|
The National Institute of Allergy and Infectious Diseases (NIAID) is seeking input from the ID community on the research agenda for a planned infectious diseases (non-HIV/AIDS) clinical trials infrastructure that leverages the successes of its existing HIV/AIDS Clinical Trials Networks.
As part of the new infrastructure, a new ID Leadership Group will be competitively selected to design and implement these trials, which will focus primarily on bacterial antibiotic resistance. The Leadership Group will also have the additional capability of responding rapidly to emerging infectious diseases such as an outbreak of SARS or pandemic influenza (see related NIAID blog post).
In early 2012, NIAID plans to issue a request for applications (RFA) from scientific investigators who are interested in forming the new ID Leadership Group. The establishment of clinical trial sites will be the subject of a subsequent funding opportunity a year later.
NIAID is requesting written comments by April 4 with input regarding a clinical research agenda for the Leadership Group. Click here for more information. NIAID is also hosting a March 7 public town hall meeting in Bethesda, Md., to solicit input. IDSA will submit written comments, and John G. Bartlett, MD, FIDSA, will represent the Society at the meeting. During the meeting, NIAID will describe and respond to questions on the plans for the non-HIV/AIDS infectious diseases network. The meeting will not be webcast, but the meeting summary and presentations will be posted online afterward.
Additionally, NIAID is planning to expand the focus of its existing HIV/AIDS Clinical Trials Networks to include AIDS co-morbidities. Tuberculosis, hepatitis B, and hepatitis C will fall under research conducted by the HIV/AIDS Leadership Groups. NIAID held a town hall meeting and received comments on the HIV/AIDS network last fall (see "The Future of the NIAID Clinical Trials Networks").
Next Article >
| 
